CerenseSM is available exclusively through a partnership between Genzyme Pharmaceuticals and Pharmidex Pharmaceutical Services.
"We are delighted to work with Pharmidex to create a platform that we believe will have a meaningful impact on the creation of new drugs for central nervous system disorders," said Dan Hayden, Senior Vice President and General Manager of Genzyme Pharmaceuticals. "CerenseSM has real potential to reduce the cost, time to market, and risk inherent in developing products for the central nervous system."
"The World Health Organization has indicated that CNS disorders are the major medical challenge of the 21st Century" said Alan Palmer, Chairman of Pharmidex, "yet treatments for most CNS disorders are either inadequate or absent. CNS is the most challenging frontier for drug discovery largely because of the complexity of the brain and the existence of the BBB. CerenseSM will greatly help the development and provision of new, safe and effective medicines for CNS disorders such as Alzheimer's disease and Parkinson's disease."
